根据美国证券交易委员会（SEC）最新备案文件显示，生物技术公司Sangamo Therapeutics Inc（纳斯达克代码：SGMO）首席财务官Prathyusha Duraibabu已于2月2日终止任职。
这一人事变动通过SEC文件正式披露，标志着该公司财务管理层的重要调整。作为首席财务官，Duraibabu曾负责监督Sangamo Therapeutics的财务战略规划、资本配置及投资者关系等核心事务。
目前公司尚未公布接任人选的具体安排。此次高管变动引发市场对这家专注于基因疗法开发的生物技术公司未来财务运营方向的关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.